QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease
Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in oral ulcers and pain and favorable area under the curve measurements, were comparable to those reported in a Phase 3 study of apremilast (Otezla(R)), despite SGX945 dosing stopping at Week 4 while apremilast required continuous administration. Soligenix noted SGX945 was well tolerated with no treatment-related adverse events observed and said it…